Abstracts tagged "autoantibodies"

Abstract Number: 1304 • 2013 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Suzanne M. Verstappen¹, Kimme L. Hyrich², Tarnya Marshall³, Anne Barton^4,5, René E.M. Toes⁶, Leendert A. Trouw⁶ and Deborah P. Symmons^4,7, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Autoantibodies against carbamylated proteins (anti-CarP) have been associated with more severe radiological damage in patients with rheumatoid arthritis (RA), including in a small subgroup…
Abstract Number: 28 • 2013 ACR/ARHP Annual Meeting
Differentiation, Activation, and Autoreactivity Of CD11c+ B Cells (ABCs)
Alice E. Wiedeman¹, Natalia V. Giltiay², Lena Tanaka³ and Keith B. Elkon³, ¹Immunology, University of Washington, Seattle, WA, ²Department of Immunology, Division of Rheumatology, University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Recently, a population of CD11c+ age-associated B cells (ABCs) was identified in normal aged female mice. These cells could be expanded following activation by…
Abstract Number: 2062 • 2013 ACR/ARHP Annual Meeting
Clinical Features and Outcome In Polymyositis Vs. Dermatomyositis Patients With The Anti-Jo-1 Autoantibody
Rohit Aggarwal¹, Diane Koontz², Zengbiao Qi³ and Chester V. Oddis⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The clinical characteristics of dermatomyositis (DM) patients possessing the anti-Jo-1 autoantibody (autoAb) are not well known. We analyzed the clinical features and prognosis of…
Abstract Number: 1288 • 2013 ACR/ARHP Annual Meeting
Development Of Antibodies Specific For Carbamylated Protein Precedes Disease Onset In Mice With Collagen-Induced Arthritis
Leendert A. Trouw¹, Bisheng Liu¹, Jing Shi¹, Diahann T.S.L. Jansen¹, Martin Hegen², Tom W.J. Huizinga¹, Jeroen N. Stoop¹ and René E. M. Toes¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pfizer, Cambridge, MA
Background/Purpose: Antibodies against citrullinated proteins are a characteristic of rheumatoid arthritis (RA). Recently, we demonstrated that autoantibodies recognizing homocitrulline containing proteins are present in sera…
Abstract Number: 26 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Directed Against Cell Surface Components In Autoimmune Disease Patients: Proposal Of a Novel ELISA For The Detection Of Anti-Endothelial Cell Antibodies
Keiji Miura¹, Ayako Kondo², Kazuo Takahashi², Daisuke Hirano², Yoshiyuki Hiki³, Shunji Yoshida², Yukio Yuzawa² and Yoshikazu Kurosawa³, ¹Institute for Comprehensive Medical Science, Fujita Health Universtiy, Toyoake, Japan, ²Fujita Health Universtiy School of Medicine, Toyoake, Japan, ³Fujita Health Universtiy, Toyoake, Japan
Background/Purpose: Sera from patients with systemic vasculitis or inflammatory conditions have been reported to contain antibodies that bind to endothelial cells (EC), i.e., AECA (anti-endothelial…
Abstract Number: 2065 • 2013 ACR/ARHP Annual Meeting
The Prevalence and Clinical Usefulness Of Anti-NXP-2 Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies
Xin Lu¹, Guochun Wang², Qinglin Peng³, Kai Yuan⁴ and Hanbo Yang⁵, ¹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, Beijing, China, ²Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ³Department of Rheumatology,, China-Japan Friendship Hospital, Beijing, China, ⁴Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, ⁵Rheumatology, China-Japan Friendship Hospital, Beijing, China
Background/Purpose: To determine the sera levels of anti-NXP-2 antibodies and their clinical association in Chinese patients with idiopathic inflammatory myopathies(IIM). Methods: Sera from 198 Chinese…
Abstract Number: 1099 • 2013 ACR/ARHP Annual Meeting
IgG Autoantibodies Against p29ING4 In Early-Stage Type I Complex Regional Pain Syndrome (CRPS) and In Other Inflammatory Diseases Involving The Joints
Niklas T. Baerlecken¹, Torsten Witte², Reinhold E. Schmidt¹, Christina Lansche¹, Michael Bernateck³ and Nils Pursche⁴, ¹Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, ²Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ³Anesthesiology, Pain Clinic, Medical University of Hannover, Hannover, Germany, ⁴Clinical Immunology and Rheumatology, Medical University of Hannover, Hannover, Germany
Background/Purpose: Complex regional pain syndrome (CRPS, a.k.a. RSD) usually occurs after limb injury, especially fractures of the distal radius and elective hand surgery. Recent research…
Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting
Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity
Hao Li¹, Hui-Chen Hsu², Qi Wu³, Jun Li³, PingAr Yang³, Yang-Xin Fu⁴ and John D. Mountz⁵, ¹Dept. Med - Immunology/Rheumatology division, University of Alabama at Birmingham, Birmingham, AL, ²Birmingham VA Medical Center, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pathology, The University of Chicago, Chicago, IL, ⁵Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…
Abstract Number: 2861 • 2013 ACR/ARHP Annual Meeting
Accounting For Parental Load and Identification Of Multiple Risk Variants For Anti-Ro Congenital Heart Block Through High-Density Genotyping Of Immune-Related Loci
Robert M. Clancy¹, Jill P. Buyon², Nathalie Costedoat-Chalumeau³, Antonio Brucato⁴, Kateri Levesque⁵, Véronique Ramoni⁶, Miranda C. Marion⁷, Mary Comeau⁸, Satria Sajuthi⁹, Paula S. Ramos¹⁰, Robert P. Kimberly¹¹, Timothy D. Howard¹² and Carl D. Langefeld¹³, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Internal Medicine, Hopital Cochin, Paris, France, ⁴Internal Medicine, USC Internal Medicine, Ospedali Riuniti, Bergamo, Italy, ⁵Medicine Interne, Hopital Cochin, Paris, France, ⁶Rheumatology, Rheumatology University of Pavia, Pavia, Italy, ⁷Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, ⁸Wake Forest University Health Sciences, Winston-Salem, NC, ⁹Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹⁰Department of Medicine, Medical University of South Carolina, Charleston, SC, ¹¹Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹²Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, ¹³Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC
Background/Purpose: Anti-Ro associated congenital heart block (CHB) exhibits a 33% concordance rate in monozygotic twins, 17.5% recurrence of disease and a high sibling risk ratio…
Abstract Number: 2066 • 2013 ACR/ARHP Annual Meeting
Distinct Arthropaties In Patients With Anti-Aminoacyl tRNA Synthetase Antibodies: Utility Of Autoantibody Profiles In Discrimination
Yuko Kaneko¹, Hironari Hanaoka¹, Michito Hirakata², Tsutomu Takeuchi¹ and Masataka Kuwana¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Medical Education Center, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Arthritis is observed frequently in patients with anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies and is usually not destructive like rheumatoid arthritis (RA). Despite several…
Abstract Number: 913 • 2013 ACR/ARHP Annual Meeting
High Throughput Epitope Mapping Of Autoantibodies In BXD2 Mice Reveals The Generation Of Autoantibodies Against Citrullinated Antigens At The Predicted Major Immunogenic Sites
Jennie Hamilton¹, Qi Wu², PingAr Yang², Hui-Chen Hsu³ and John D. Mountz⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased polyreactive B cells have been identified in patients with systemic lupus erythematous (SLE) and rheumatoid arthritis (RA). Such autoantibodies (autoAbs) were also identified…
Abstract Number: 10 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Navid Zohoury¹, Munther A. Khamashta², Tatsuya Atsumi³, Jacek Musial⁴, Toshiyuki Watanabe⁵, Maria Papp⁶, Concepción González-Rodríguez⁷, Roger Albesa¹, Gary L. Norman¹, Pier-Luigi Meroni⁸ and Michael Mahler¹, ¹Research, INOVA Diagnostics, San Diego, CA, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁴Depment of Medicine, Jagiellonian University Medical College, Krakow, Poland, ⁵Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ⁶MHSCInstitute of Medicine, Department of Gastroenterology, University of Debrecen, Debrecen, Hungary, ⁷University Hospital Virgen Macarena, Sevilla, Spain, ⁸Int Medicine, University of Milan, Milano, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 2862 • 2013 ACR/ARHP Annual Meeting
Autoantigen Microarray Analysis Of Sera From New-Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis
Imelda Balboni¹, David Haddon², Vivian Diep², Cindy Limb² and Paul Utz², ¹Pediatrics, Stanford University School of Medicine, Palo Alto, CA, ²Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease characterized by the production of autoantibodies directed against highly-conserved nuclear antigens. 15-20% of SLE…
Abstract Number: 1890 • 2013 ACR/ARHP Annual Meeting
Chemokine Receptor Polymorphisms On Chromosome 3 Are Associated With Anticitrullinated Protein Antibody Specificities In African Americans With Rheumatoid Arthritis
Richard J. Reynolds¹, Maria I. Danila², Jeremy Sokolove³, William H. Robinson⁴, Doyt L. Conn⁵, Beth L. Jonas⁶, Leigh F. Callahan⁷, Larry W. Moreland⁸, Richard D. Brasington⁹, Edwin A. Smith¹⁰, Peter K. Gregersen¹¹ and S. Louis Bridges Jr.¹², ¹Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ³VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁴Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁵Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ⁶Thurston Arthritis Research Ct, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ¹⁰Dept of Med Div of Rheum, Med Univ of South Carolina, Charleston, SC, ¹¹Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ¹²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: ACPA antibody specificities to citrullinated autoantigens (e.g., histones, vimentin, fibrinogen) are associated with the preclinical phase of RA and may predict the onset of…
Abstract Number: 921 • 2013 ACR/ARHP Annual Meeting
Blocking The Complement Receptor 2 (CR2) Ligand-Receptor Interaction With a Novel Mouse Anti-Mouse CR2 Monoclonal Antibody Decreases Antigen-Specific Humoral Immune Responses and The Evolution Of Collagen-Induced Arthritis
Rosa Rodriguez¹, Liudmila Kulik¹, Joshua Thurman², Jonathan Hannan¹, Steve Tomlinson³ and V. Michael Holers¹, ¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ²Renal Division, University of Colorado School of Medicine, Aurora, CO, ³Microbiology and Immunology, Medical University of South Carolina, Charleston, NC
Background/Purpose: The CR2/CD19 complex on B cells serves as a co-receptor for membrane IgM and amplifies B cell responses through physical associations of the bound…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.